Fatmawati Fatmawati
Department Of Biochemistry And Medical Chemistry, Faculty Of Medicine, Universitas Sriwijaya Palembang

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

The role of interleukin-17 in vulvovaginal candidiasis (VVC): literature review Rizka Amelia; Susilawati Susilawati; Fatmawati Fatmawati
Jurnal Ners Vol. 10 No. 2 (2026): APRIL 2026
Publisher : Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/jn.v10i2.57356

Abstract

Vulvovaginal candidiasis (VVC) is one of the most prevalent infections of the female genital tract. According to epidemiological data, almost 75% of women will at some point in their lives contract VVC. The main causative agent is Candida albicans. One of the main mediators is IL-17, a pro-inflammatory cytokine that is essential to the immunopathogenesis of VVC. Although IL-17 is essential for antifungal immunity, excessive or prolonged activation may lead to pathogenic inflammation and recurrence. This intricacy highlights the necessity of more research into the IL-17 regulation mechanisms in VVC and its possible use as a therapeutic target. Research published between 2020 and 2025 was included in a literature search that was done using databases including Scopus, PubMed, and Google Scholar. Eight of the 64 examined papers satisfied the requirements for inclusion. IL-17 is a key mediator in the immunopathogenesis of vulvovaginal candidiasis (VVC), according to preclinical, mechanistic, and clinical research. Treatments for VVC either increase or decrease IL-17 responses, and genetic variations in the IL-17/IL-23 axis are associated with a higher risk of developing the disease. In conclusion, IL-17 plays a key role in the pathophysiology of VVC. It is a promising biomarker and therapeutic target since it influences both immunological modulation and vulnerability through therapeutic treatments and genetic differences in the IL-17/IL-23 axis.
Arcangelisia flava L. Merr. Aqueous Extract Potential as a Xanthine Oxidase Inhibitor Fatmawati; Subandrate; Rini Yana; Maharani Puspita Sari HS; Nadia Permata Sari
Global Medical & Health Communication (GMHC) Vol. 13 No. 3 (2025): Accredited Sinta 2
Publisher : UPT Publikasi Ilmiah Universitas Islam Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/gmhc.v13i3.7968

Abstract

Arcangelisia flava L. Merr. contains several secondary metabolites, including berberine and palmatine, which are known to have potential as inhibitors of xanthine oxidase (XO). XO is an enzyme involved in purine metabolism, catalyzing the oxidation of hypoxanthine to xanthine and then xanthine to uric acid. The community uses the stems and leaves of A. flava to maintain health by brewing them in hot water. The potential of this plant to inhibit XO using an aqueous solvent has never been studied. This study aims to assess the xanthine oxidase inhibitory activity of water extracts derived from the stems and leaves of A. flava. The study design was an in vitro experimental study conducted in the Basic Medical Chemistry Laboratory of Universitas Sriwijaya from September to December 2023. The aqueous extract of stems and leaves from A. flava was tested using an in vitro xanthine oxidase inhibitory assay, as observed through a decrease in uric acid levels via UV absorption. The stem extract exhibited stronger XO inhibition (IC50=21.15 μg/ml, 95% CI=19.87–22.51) compared with the leaf extract (IC50=68.42 μg/ml, 95% CI=61.35–76.28). The inhibitory activity of the stem extract approached that of allopurinol (IC50=16.78 μg/ml, 95% CI=15.62–18.02). In conclusion, the aqueous stem extract of A. flava demonstrates significantly XO inhibitory activity than the aqueous leaf extract.